Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a M4 Positive Allosteric Modulator.
Abbott Directed to Provide Prescribing Details for Triamcinolone Hexacetonide Pre-Filled Syringe The Subject Expert Committee (SEC) under …
Trump Rejects Vice Presidential Run Donald Trump has ruled out running for vice president in the 2028 American election. Aboard Air…
Utah's Olympic Organizers in NYC Leaders of Utah's 2034 Winter Games are attending the U.S. Olympic and Paralympic Committee Team USA Medi…
CTD-ILD Burden on Older Patients and Women The incidence and prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-…
Saudi Railway Company and Ericsson Partner on 5G Technology The Saudi Railway Company (SAR) has signed a memorandum of understanding (MoU)…
Chick-fil-A Introduces Hospital Vending Machine Fast-food giant Chick-fil-A has launched its first-ever vending machine, sparking debate a…
Waaree Secures 692MW Solar Module Deals Waaree Energies, an Indian solar manufacturer, has secured four solar module supply contracts tota…
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial Zenas BioPharma, a clinical-stage global biopharmaceutical company…
Can the Warriors Maximize Stephen Curry's Remaining Years? Stephen Curry remains an exceptional player, and his supporting cast has improv…
Bird Flu Strain H9N2: A Potential Threat to Humans A team of scientists has raised concerns about the H9N2 bird flu virus, which has adapt…